Written by Amelia Willson
Medically Reviewed by Dr. Paul Hetrick, PharmD
Published: Apr 8, 2025

Key takeaway: Semaglutide for weight loss (Wegovy) starts at 0.25mg weekly and escalates every 4 weeks to a maximum maintenance dose of 2.4mg over approximately 17 weeks. Using the correct dose matters — too low limits effectiveness, too fast causes more side effects. A licensed provider determines the right dose and pace for your situation.
Better known by the brand names Wegovy and Ozempic, semaglutide mimics a natural hormone that helps regulate appetite and blood sugar levels. Semaglutide can be transformative for weight loss, but using the right dose matters. That’s why we put together a detailed semaglutide weight loss dosage chart.
Ready to explore your GLP-1 options? Klarity’s licensed providers can evaluate whether semaglutide, tirzepatide, or other weight loss medications may be right for you — fully online, same-day appointments with 2,000+ providers. Many insurance plans may cover your visit. See if you may qualify →
| Week | Wegovy Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.25mg weekly | Starting dose; allows body to adjust; appetite suppression mild |
| Weeks 5-8 | 0.5mg weekly | Appetite suppression increases; most patients notice clearer changes |
| Weeks 9-12 | 1.0mg weekly | Significant appetite and satiety changes; weight loss accelerates |
| Weeks 13-16 | 1.7mg weekly | Near maintenance dosing; strong appetite suppression |
| Week 17+ | 2.4mg weekly | Maximum approved maintenance dose for weight loss |
| Step | What Happens | Klarity’s Role |
|---|---|---|
| 1. Online evaluation | Provider reviews BMI, health history, current medications, goals | Fully online; same-day appointments with 2,000+ providers |
| 2. Prescription decision | Provider determines if semaglutide is appropriate for your situation | Independent clinical decision by licensed provider |
| 3. Starting dose | 0.25mg Wegovy prescribed; sent to pharmacy | Provider coordinates prescription |
| 4. Dose escalation | Every 4 weeks if tolerated; slower escalation available if side effects are significant | Provider monitors and adjusts as needed |
| 5. Insurance check | Verify if your plan may cover Wegovy or compounded semaglutide | Many insurance plans may cover your visit. Coverage varies by plan. |
Compounded semaglutide uses the same active ingredient as Wegovy but is produced by compounding pharmacies. Following FDA regulatory changes in 2025, compounded semaglutide must come from an FDA-registered 503B outsourcing facility. Dosing may vary from brand-name formulations — always follow your provider’s specific instructions and do not self-adjust doses.
Dosage guidance for semaglutide has been refined in 2025-2026 based on new clinical findings and new formulations entering the market.
Oral semaglutide dosage for weight management (2026). The FDA approved higher-dose oral semaglutide for chronic weight management in early 2026. Oral formulations require strict timing — taken on an empty stomach with no more than 4 oz of plain water, 30 minutes before any food or other medications. Dosage titration for oral semaglutide is similar in concept to injectable but follows its own schedule; a provider determines appropriate escalation.
Slower titration validated for tolerability. A 2025 real-world analysis confirmed that extending the titration phase by 4-8 weeks (staying at each dose longer before escalating) significantly reduced GI side effects without meaningfully affecting 52-week weight loss outcomes. If you experience significant nausea, ask your provider about a modified escalation schedule.
Tirzepatide dosage comparison. For patients comparing semaglutide vs tirzepatide dosing: tirzepatide (Zepbound) starts at 2.5mg and escalates to a maximum of 15mg weekly, with a different mg scale. SURMOUNT-5 data (2025) shows tirzepatide achieves approximately 47% greater average weight loss than semaglutide over a comparable period. A provider evaluation helps determine which dosing trajectory may be right for you.
Retatrutide pipeline. The investigational triple agonist retatrutide is in Phase 3 trials with dosage regimens still being optimized. Its early data showing up to 24% body weight reduction suggests a different dose-response curve from current semaglutide options.
The starting dose of Wegovy (semaglutide) for weight loss is 0.25mg weekly for the first 4 weeks. This low starting dose allows the body to adjust and minimizes side effects before escalation.
The maximum FDA-approved maintenance dose of Wegovy (semaglutide) for weight loss is 2.4mg weekly, typically reached around week 17 following the standard escalation schedule.
2.4mg is the maximum approved dose for Wegovy. If weight loss has plateaued at 2.4mg, a provider may evaluate whether a medication switch (e.g., to tirzepatide), dietary adjustment, or other intervention is appropriate rather than increasing the dose further.
Klarity’s 2,000+ licensed providers offer fully online evaluations with same-day appointments. A provider reviews your health history and determines if semaglutide is appropriate for your weight loss goals.
Many commercial insurance plans may cover Wegovy for patients who meet BMI and health condition criteria. Coverage varies significantly by plan and insurer. Verify your benefits before booking.
Ready to explore your GLP-1 options? Klarity’s licensed providers can evaluate whether semaglutide, tirzepatide, or other weight loss medications may be right for you — fully online, same-day appointments with 2,000+ providers. Many insurance plans may cover your visit. See if you may qualify →
Coverage varies by plan. Verify your benefits before booking.
Find the right provider for your needs — select your state to find expert care near you.